General Economic Health & Investor Risk Appetite: Upcoming US Q4 GDP and February PCE price data releases will influence overall market sentiment. As a biotechnology company, AUPH's performance is sensitive to investor confidence in growth stocks, which typically benefits from positive economic indicators.

Inflationary Pressures & Interest Rates: Expected US CPI and Core CPI data releases are critical. Sustained inflation could lead to higher interest rates, impacting the cost of capital for Aurinia's research and development and potentially dampening the valuation of future earnings for growth-oriented biotech firms.

Healthcare Sector Specific Trends: Beyond general economic factors, the biotechnology and pharmaceutical sector is influenced by ongoing regulatory developments, drug pricing debates, and competitive dynamics within specific disease markets such as autoimmune diseases, where Aurinia's flagship product, LUPKYNIS, operates.